Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine
- Development stage
- Approved
- Lead developer
- KM Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
DTaP (Diphtheria, Tetanus, and acellular Pertussis) vaccine is a combination vaccine used for active immunization against infections caused by *Corynebacterium diphtheriae*, *Clostridium tetani*, and *Bordetella pertussis*. The acellular pertussis component (aP) consists of purified antigens such as pertussis toxoid (PT), filamentous hemagglutinin (FHA), and often pertactin (PRN) and fimbriae (FIM), which provide protective immunity with a lower risk of adverse reactions compared to older whole-cell pertussis vaccines. In Japan, where the IM-PreP study is conducted, DTaP vaccines are traditionally administered via subcutaneous injection, whereas intramuscular injection is the standard in many other regions. Clinical studies evaluate the safety and immunogenicity of DTaP in specific populations, including pregnant women receiving immunosuppressive therapy, to ensure maternal protection and the transfer of passive immunity to infants.
- Brand names
- DaptacelInfanrixAcel-ImuneTripediaQuattrovacTetrabik
- Other names
- DTaPDPT vaccineacellular pertussis-diphtheria-tetanus vaccineDTPaDTaP pertussis vaccine
02
Targets
Fimbrial antigen type 3PRN (Pertactin)FHA (Filamentous hemagglutinin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine.